As of December 31, 2025, the Company’s Omnibus Equity Incentive Plan approved by the Board on August 9, 2024 (the “Omnibus Plan”), which was most recently approved by Stockholders at the Company’s annual stockholder meeting held on September 30, 2024.

Under the Omnibus Plan, the maximum number of Shares issuable at any time pursuant to outstanding awards will be equal to: (a) 10% of the outstanding common shares issued pursuant to options; and (b) 9,142,257 issued pursuant to share units (which represents 10% of the outstanding common shares as of the date the plan was approved by the Board), or such other number as may be approved by the Exchange and the shareholders of the Company from time to time. For so long as the Company is listed on the Exchange or on another exchange that requires the Company to fix the number of Common Shares to be issued pursuant to Share Units, the maximum number of Common Shares available for issuance pursuant to the settlement of RSUs, DSUs and PSUs together will be an aggregate of 9,142,257 Common Shares. 

The maximum number of common shares for which awards may be issued to any one participant in any 12-month period shall not exceed 5% of the outstanding common shares, unless the Company obtains disinterested shareholder approval as required by the policies of the Exchange. The aggregate number of common shares for which awards may be issued to any one consultant within any 12-month period shall not exceed 2% of the outstanding Common Shares, calculated on the date an Award is granted to the consultant. The aggregate number of Common Shares for which Options may be issued to any persons retained to provide Investor Relations Activities (as defined by the Exchange) within any 12-month period shall not exceed 2% of the outstanding Shares, calculated on the date an Option is granted to such persons.

Further, unless disinterested shareholder approval as required by the policies of the Exchange is obtained: (i) the maximum number of Common Shares for which Awards may be issued to insiders of the Company (as a group) at any point in time shall not exceed 10% of the outstanding common shares; and (ii) the aggregate number of awards granted to insiders of the Company (as a group), within any 12-month period, shall not exceed 10% of the outstanding Common Shares, calculated at the date an award is granted to any insider.

During the year ended December 31, 2025, the Company did not grant any stock options and recorded $Nil (2024 - $5,969) of share-based compensation for vested portion of options that were previously granted.

The changes in stock options are as follows:

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options that were in-the-money at December 31, 2025.

As of December 31, 2025, there were Nil options outstanding.